Aevi Genomic Medicine (GNMX) announced Monday morning that its SAGA trial of AEVI-001 in adolescents with mGluR mutation positive ADHD did not meet the primary endpoint of reduction on the ADHD rating scale compared to placebo.
Aevi Genomic Medicine gapped open dramatically lower Monday morning and is now down 3.16 at $2.28 on the highest volume of the year. The stock has plunged to a new low for the year.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org